Tag Archives: Geodon

Post-Approval Regulatory Priorities: Progress or Pile-Up?

An enduring falsehood about the pharmaceutical industry is that the heavy lifting ends with a successful new drug registration. What comes after is the equivalent of a well-funded retirement, where providers embrace the therapy, payers meet the price, and patients push the boundaries of clinical practice toward lucrative new indications. The reality, however, is starkly […]
Posted in Regulatory | Also tagged , , , , | 2 Comments

Avandia Trial in Trouble

GSK’s Avandia just won’t stay out of the news. Now comes a report from The Wall Street Journal that the FDA is considering dealing the beleaguered diabetes drug another blow by stopping one of its safety trials. The TIDE trial, which received approval in 2007, pits Avandia (rosiglitazone) against Takeda’s Actos (pioglitazone), a drug that […]
Posted in Strategy | Also tagged , , , , , , | Leave a comment
  • Categories

  • Meta